However, additional references suggest that certain risks like heart failure and related hospitalisation, and pancreatitis, may be increased with the use of DPP-4 inhibitors compared to other anti-diabetic treatments, independently of age group [60–63]. The gene discussed is DPP4; the disease is pancreatitis.